Clinical trials: RDS
Acute Lung Injury, Acute Respiratory Distress Syndrome
Airway Pressure Release Ventilation in Acute Lung Injury
The purpose of this study is to compare airway pressure release ventilation (APRV) to conventional mechanical ventilation (MV) in patients with acute lung injury (ALI) to determine if APRV can reduce agitation, delirium, and…
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
- Trial name
- NCT00750204
- Testing
- APRV, Conventional MV
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
COVID, Corona Virus Infection
hCT-MSCs for COVID19 ARDS
This is a 50 patient, Phase 1/2a multi-center pilot study to test the safety and to describe the preliminary efficacy of intravenous administration of allogenic human cord tissue mesenchymal stromal cells (hCT-MSC) as an…
- Conditions
- COVID, Corona Virus Infection, COVID19
- Trial name
- NCT04399889
- Testing
- Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Joanne Kurtzberg, MD
Acute Respiratory Distress Syndrome
Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome
A randomized, concurrent controlled trial to assess if adding sigh breaths to usual invasive mechanical ventilation of victims of trauma who are at risk of developing ARDS will decrease the number of days they require invasive…
- Trial name
- SiVent (NCT02582957)
- Testing
- Sigh breaths
- Where
- 15 sites in United States
- Volunteers
- 524 people
- Sponsor
- University of Minnesota
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
The primary aim of this study is to quantify and compare changes in lung volumes (as measured by functional residual capacity) in premature infants stable on continuous positive airway pressure (CPAP), and then randomized to two…
- Trial name
- NCT02249143
- Testing
- CPAP and room air
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
Respiratory Distress Syndrome, Newborn
Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation
In this study, newborn babies with respiratory distress syndrome (RDS), receiving oxygen via nasal CPAP, and needing surfactant treatment will be randomized to standard delivery of surfactant via and endotracheal tube…
- Trial name
- NCT01042600
- Testing
- Endotracheal tube insertion, Laryngeal mask airway insertion
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Albany Medical College
Respiratory Distress Syndrome
Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
Premature infants frequently have trouble breathing after birth. If the respiratory disorder is caused by surfactant deficiency or dysfunction, the disease is treated with a medication called surfactant that is given to the…
- Trial name
- NEOSURF (NCT02834624)
- Testing
- Poractant alfa, calfactant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Missouri-Columbia
Acute Respiratory Distress Syndrome, Influenza
STIP: Statin Trial for Influenza Patients
To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Trial name
- STIP (NCT00970606)
- Testing
- Rosuvastatin (crestor)
- Where
- 21 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gordon Bernard
Acute Respiratory Distress Syndrome, Adult
Add-on Reparixin in Adult Patients With ARDS
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to…
- Trial name
- NCT05496868
- Testing
- Reparixin 600mg
- Where
- 40 sites in United States, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID, Sars-CoV2
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
This clinical trial will enroll participants that have pneumonia caused by the COVID-19 virus. During the study patients will receive 7 to up to 14 days of defibrotide.
- Conditions
- COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- NCT04530604
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gregory Yanik
Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day.
- Conditions
- Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections, ARDS, Human
- Trial name
- MP-C19 (NCT04323592)
- Testing
- Methylprednisolone, standard care
- Where
- Italy
- Volunteers
- 173 people
- Sponsor
- University of Trieste
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Respiratory Distress Syndrome, Vitamin D Deficiency
Vitamin D to Improve Outcomes by Leveraging Early Treatment
Vitamin D deficiency is a common, potentially reversible contributor to morbidity and mortality among critically ill patients. We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D3…
- Conditions
- Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
- Trial name
- VIOLET (NCT03096314)
- Testing
- Vitamin D3
- Where
- 47 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Massachusetts General Hospital
Covid19
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729593
- Testing
- Remdesivir, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
Acute Lung Injury (ALI), ARDS
Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS
Electrical impedance tomography (EIT) monitoring has been researched as a method to determine the spatial impedance distribution in a body cross section, but has yet to become an established clinical tool.
- Trial name
- NCT01272882
- Testing
- Electrical Impedance Tomography monitoring
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Christiana Care Health Services
Acute Respiratory Distress Syndrome, Covid19
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
- Trial name
- NCT04524962
- Testing
- Descartes 30
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cartesian Therapeutics